Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

PMV Pharmaceuticals Inc
Healthcare
P/NCAV
0.48x
Ticker
PMVP
Exchange
NASDAQ
Country
United States
Close
1.8 $
Mkt Cap
86.7M $
EV
49.0M $
NCAV Burn Rate
18.8%
Current Ratio
14.78
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-0.6x
EV/FCF
-0.9x
Dilution
2.2% p.A
Total Net Income
-277.5M $
Cheapness
99.0%
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 is a tumor suppressor protein known as the guardian of the genome, and normal, or wild type, p53 has the ability to eliminate cancer cells. It is leveraging its precision oncology platform to develop a pipeline of orally available, potent and highly selective small molecule product candidates that target p53 mutations or other p53-related cancers. Its lead product candidate, PC14586 (rezatapopt), is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. In preclinical studies, PC14586 has shown selective on-target activity, which functions in cells with the p53 Y220C mutation and exhibited robust anti-tumor activity evidenced by potent tumor growth inhibition and strong tumor regression as a single agent.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average